Comment on “Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis”
- 7 November 2021
- journal article
- letter
- Published by Springer Nature in CNS Drugs
- Vol. 35 (12) , 1333-1334
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- RoB 2: a revised tool for assessing risk of bias in randomised trialsBMJ, 2019
- Viewpoint: taking into account risks of random errors when analysing multiple outcomes in systematic reviews2016
- Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methodsBMC Medical Research Methodology, 2014
- The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence synthesesJournal of Clinical Epidemiology, 2013
- GRADE guidelines: 15. Going from evidence to recommendation—determinants of a recommendation's direction and strengthJournal of Clinical Epidemiology, 2013
- Pooling health‐related quality of life outcomes in meta‐analysis—a tutorial and review of methods for enhancing interpretabilityResearch Synthesis Methods, 2011
- Effect of Fluoxetine on Anger in Symptomatic Volunteers With Borderline Personality DisorderJournal of Clinical Psychopharmacology, 1995
- A trial of carbamazepine in borderline personality disorderEuropean Neuropsychopharmacology, 1994
- Borderline and Schizotypal Personality Disorders Treated With Low-Dose Thiothixene vs PlaceboArchives of General Psychiatry, 1986
- Pharmacological prevention of suicidal behaviourJournal of Affective Disorders, 1982